Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, is dedicated to the development and commercialization of various T-cell-based immunotherapies and peptide-based vaccines for the treatment of hematologic malignancies and solid tumor indications. The company is headquartered in Houston, Texas.
| Revenue (TTM) | $3.55M |
| Gross Profit (TTM) | $-5.26M |
| EBITDA | $-11.79M |
| Operating Margin | -267.90% |
| Return on Equity | -76.90% |
| Return on Assets | -40.50% |
| Revenue/Share (TTM) | $0.19 |
| Book Value | $0.73 |
| Price-to-Book | 1.70 |
| Price-to-Sales (TTM) | 4.89 |
| EV/Revenue | 0.199 |
| EV/EBITDA | -0.22 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -51.00% |
| Shares Outstanding | $16.67M |
| Float | $13.74M |
| % Insiders | 5.49% |
| % Institutions | 23.80% |
Volatility is currently expanding
MARKER THERAPEUTICS (MRKR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
UGP, SCSC, MRKR, SLGL and MEOH have been added to the Zacks Rank #1 (Strong Buy) List on October 16, 2026.
HOUSTON, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company developing multi-antigen recognizing (MAR)-T cell therapies for the treatment of hematologic malignancies and solid tumors, today highlighted the expanded infrastructure, technical expertise and manufacturing capabilities supporting its lead program, MT-601 (neldaleucel), following the combination of Cellipont Bioservices and Kincell Bio to form Kincellis Advanced Therapies.
Indivior, Aurinia, Ironwood, Altimmune and Marker have been highlighted in this Industry Outlook article.
Innovation is at its peak in the Zacks Medical-Drugs industry. INDV, AUPH, IRWD, ALT and MRKR may prove to be good additions to one's portfolio.
MARKER THERAPEUTICS (MRKR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on MRKR and any ticker you trade — then tracks every position and per-strategy win rate.
